Chapter 5 - The First Board Meeting
Monday morning at 9:00 a.m. sharp, the glass-walled boardroom of Blackwood Medical Group on the thirty-fifth floor of the Sterling Tower was packed to capacity.
The long mahogany table was surrounded by senior vice presidents, medical directors, and regional compliance officers who had spent the weekend frantically reading emergency legal briefs sent down by Vance & Sterling.
When the double doors opened, I walked in first.
I wore a tailored navy wool pantsuit, a crisp white silk blouse, and—by deliberate choice—no wig. My hair was beginning to grow back in soft, dark fuzz across my scalp, but I didn't bother hiding it beneath silk or synthetics. I wore my survival like a crown.
Behind me walked Ethan, acting in his new capacity as Executive Vice President of Strategic Operations, followed by Julian Vance carrying a massive leather portfolio of forensic audits.
We took our seats at the head of the table.
Sitting halfway down the left side, looking small, pale, and entirely defeated, was Margaret Blackwood. She had managed to secure a temporary injunction allowing her to attend as a minority board member holding her remaining three percent non-voting stock, but her voice carried none of its former thunder.
“Good morning, everyone,” I said, my voice cutting through the murmurs of the room with the quiet authority of a majority shareholder holding fifty-one percent of the voting rights.
I opened my folder, sliding a set of printed documents toward each director.
“Before we discuss the Q3 financial projections,” I began, leaning forward and resting my forearms on the polished wood, “we need to address a few structural inefficiencies that have been quietly bleeding this company dry for the past five years.”
Across the table, Margaret’s legal representative—a nervous corporate litigator hired at the last minute—cleared his throat. “Mrs. Hart—if I may—my client wishes to formally contest the validity of the debt-call executed on Friday, citing potential conflicts of interest regarding the Sterling Capital acquisition—”
“You may file whatever motions you like with the federal bankruptcy court, counselor,” Julian Vance interrupted smoothly, not even looking up from his legal pad. “The judge signed the validation order at 7:30 this morning. The acquisition is permanent, legal, and completely unassailable.”
Margaret slumped back in her ergonomic chair, her eyes fixed on the grain of the wooden table as if she wished the earth would open up and swallow her whole.
“Now,” I continued, ignoring the lawyer entirely as I flipped to page two of my briefing. “Let’s talk about the R&D budget for our oncology division. For the last three years, funding for targeted immunotherapy trials was systematically redirected into executive bonuses and offshore subsidiaries controlled by former management.”
I paused, letting my eyes sweep slowly around the room, making direct eye contact with every department head who had once nodded along with Margaret’s corrupt directives.
“Effective immediately,” I stated clearly, “those funds are being restored, doubled, and redirected toward clinical trials for uninsured cancer patients across the state. Furthermore, every executive who participated in the unauthorized asset-stripping of this division will be subjected to an independent forensic audit by Vance & Sterling.”
A heavy, terrified silence settled over the room. Not a single executive dared to raise a hand, object, or clear their throat. They looked at me not as a young woman who had recently beaten cancer, but as the apex predator who had just devoured the old guard without breaking a sweat.
“Is there any new business?” I asked, looking around the table.
May you like
Silence.
“Then the meeting is adjourned,” I said, closing my folder with a sharp clack. “Ethan, Julian, please stay behind. Everyone else is dismissed.”
